GSK plc
British multinational pharmaceutical and biotechnology company, formed in 2000 through the merger of Glaxo Wellcome and SmithKline Beecham; manufactures pharmaceuticals, vaccines, and consumer healthcare products across asthma, cancer, infections, diabetes, and mental health.
相关临床试验
3904
205 进行中
药物批准
131
批准总数
监管机构
1
监管机构数
成立时间
2000
尚未招募
43
1.1%
No Longer Available
5
0.1%
终止
240
6.2%
招募中
91
2.3%
暂停
2
0.1%
Available
2
0.1%
撤回
116
3.0%
进行中（未招募）
162
4.2%
Unknown
7
0.2%
已完成
3236
82.9%
- The ISS National Laboratory has surpassed 1,000 sponsored payloads delivered to the orbiting laboratory since August 2011, a milestone reached during NASA's Northrop Grumman Commercial Resupply Services 24 mission. - The space-based research program has generated more than 675 peer-reviewed publications, with over 20% appearing in top-tier journals, underscoring its scientific impact. - Global pharmaceutical companies including Merck & Co., AstraZeneca, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, and Sanofi have leveraged microgravity to advance drug discovery, vaccine development, and drug-delivery technologies. - Startups using the ISS National Lab have raised nearly $3 billion in funding after completing their spaceflight projects, highlighting the platform's role as a commercialization incubator.
- The U.S. FDA granted Fast Track Designation to BV100, BioVersys' lead clinical asset, for treating VABP and HABP caused by carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC). - BV100 is a novel intravenous formulation of rifabutin that uses the siderophore pathway to target the RNA-polymerase enzyme in Gram-negative bacteria, offering a non-β-lactam therapy option. - The designation follows a Phase 2 study showing a 50% reduction in mortality versus best available therapy, with BV100 now in a pivotal Phase 3 trial (RIV-TARGET). - CRABC is a WHO priority-1 critical pathogen with mortality rates reaching 50% globally, underscoring the urgent unmet medical need for new antimicrobials.
- GSK's new CEO Luke Miels is executing a three-year, multibillion-dollar restructuring to save roughly $2.5 billion annually ahead of looming patent expirations on blockbuster drugs like dolutegravir. - Novo Nordisk's Maziar Mike Doustdar is working to regain obesity-market momentum lost to Eli Lilly, buoyed by strong uptake of the Wegovy pill despite recent pipeline setbacks. - Sanofi's Dr. Belén Garijo is steering the company toward a post-Dupixent future, with the blockbuster facing loss of exclusivity as soon as 2031. - All three leaders took the helm within the last year at pivotal moments, each aiming to set up the next phase of growth for their companies.
- Manufacturing accounts for roughly 80% of a pharmaceutical company's environmental footprint, making the factory floor the critical intervention point for meaningful change. - Eight leading APAC CDMOs are integrating renewable electricity, water reuse, waste recovery, green chemistry and continuous manufacturing into core production strategy rather than isolated initiatives. - The global sustainable drug manufacturing market is projected to grow from USD 105.8 billion in 2026 to USD 248.2 billion by 2036 at an 8.9% CAGR. - Scope 3 emissions, supplier engagement and internal carbon pricing are emerging as the next frontier, with WuXi AppTec reporting 82.14% of emissions from Scope 3.
- With the CDC largely silent this fall, the American Medical Association and the University of Minnesota's Vaccine Integrity Project published independent reviews in JAMA to guide flu, Covid-19, and RSV immunization. - New recommendations from the AAP, AAFP, ACOG, and IDSA advise RSV immunization for high-risk adults 50+, everyone over 75, pregnant people, and infants, plus annual flu shots for everyone 6 months and older. - Updated Covid-19 vaccines targeting the XFG Omicron subvariant are recommended for adults, with a second dose six months later for those 65 and older, and insurers have indicated coverage without cost sharing. - The first mRNA flu vaccine is newly available for adults 50 and older, while ACOG extended the maternal RSV vaccine window through March 1 due to a later, more severe RSV season.
- Vivace Therapeutics announced leadership appointments and FDA "Safe to Proceed" clearance as it prepares to advance VT3989 into the pivotal Phase 3 sTEADfast trial in mesothelioma. - VT3989 is a first-in-class, orally administered TEAD autopalmitoylation inhibitor targeting the Hippo signaling pathway, with Fast Track and Orphan Drug designations from the FDA. - The Phase 3 registrational study will enroll mesothelioma patients previously treated with both combination immunotherapy and combination chemotherapy, with initiation planned for later this year. - Craig Gibbs, PhD, MBA, was named President and CEO, Ellen Lubman, MBA, joined as Chief Business and Strategy Officer, and Tim Clackson, PhD, was appointed to the Board of Directors.
- ModeX Therapeutics, led by CEO Gary Nabel, is developing a bivalent vaccine against Epstein-Barr virus (EBV), now in Phase 1 clinical trials with partner Merck. - The vaccine targets two viral entry pathways—GP350 for B cells and the GH/GL/GP42 trimer for epithelial cells—aiming for sterilizing immunity that prior single-antigen efforts failed to achieve. - EBV is implicated in roughly 200,000 cancer cases globally each year, as well as multiple sclerosis, lupus, and rheumatoid arthritis, underscoring the vaccine's potential to prevent chronic disease. - The program leverages surrogate markers such as viral load and immune markers to compress the timeline, potentially avoiding decades-long longitudinal cancer studies.
- GSK's infringement claims over mRNA delivery patent EP 2 590 626 will be heard at The Hague Local Division of the Unified Patent Court on 1 and 3 September, targeting Moderna, BioNTech and Pfizer. - The dispute stems from GSK's decision to enforce its mRNA patent portfolio against the manufacturers of the successful Covid-19 vaccines, with parallel litigation also underway in the US, Ireland and the UK. - The Hague has emerged as the leading UPC venue for pharmaceutical patent litigation, handling roughly a quarter of all such cases despite accounting for only about 12% of overall filings. - A prior CureVac–BioNTech–Pfizer settlement, involving a $370 million payment and 1% royalty to GSK, expressly reserved GSK's own patent enforcement rights against Pfizer and BioNTech.
- A Nature correspondence argues that pre-clinical data interpretation must be grounded in clinical context to avoid misleading translational conclusions. - The exchange involves researchers from The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, and The University of Chicago. - The reply clarifies that the Matters Arising discussion concerns the broader clinical implications of findings rather than mechanistic aspects. - Authors disclose extensive industry relationships, including consulting, funding, and patent interests relevant to radiation oncology and cancer research.
- XPRIZE announced 20 Finalist Teams advancing in the $101 million Healthspan competition, with 10 teams each receiving $1 million Milestone 2 awards to accelerate clinical development. - The competition aims to restore muscle, cognition, and immune function by a minimum of 10 years in adults aged 50–90, with treatments lasting one year or less. - UC San Diego's Stein Institute will serve as the Central Laboratory and Biorepository, providing standardized multi-omics analysis and biomarker profiling for all finalist teams. - Coordinated clinical trials will run from 2026 to 2029, with the grand prize of up to $81 million to be awarded in 2030.
